Boston Scientific (NYSE:BSX)‘s stock had its “buy” rating restated by investment analysts at BMO Capital Markets in a research note issued on Tuesday. They currently have a $32.00 price target on the medical equipment provider’s stock. BMO Capital Markets’ price objective points to a potential upside of 24.95% from the stock’s current price.

BSX has been the subject of a number of other reports. BidaskClub cut shares of Boston Scientific from a “hold” rating to a “sell” rating in a report on Saturday, August 26th. Stifel Nicolaus reaffirmed a “buy” rating and issued a $32.00 target price on shares of Boston Scientific in a report on Monday, September 25th. SunTrust Banks set a $33.00 target price on shares of Boston Scientific and gave the company a “buy” rating in a report on Monday, December 4th. Royal Bank of Canada reaffirmed a “buy” rating and issued a $31.00 target price on shares of Boston Scientific in a report on Friday, September 1st. Finally, Zacks Investment Research raised shares of Boston Scientific from a “sell” rating to a “buy” rating and set a $33.00 target price for the company in a report on Friday, October 20th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating, fourteen have given a buy rating and one has issued a strong buy rating to the company. Boston Scientific presently has a consensus rating of “Buy” and a consensus price target of $31.03.

Boston Scientific (NYSE:BSX) traded up $0.11 during trading on Tuesday, hitting $25.61. 11,201,624 shares of the stock traded hands, compared to its average volume of 7,036,955. Boston Scientific has a 1-year low of $21.03 and a 1-year high of $29.93. The stock has a market cap of $35,387.26, a PE ratio of 21.12, a P/E/G ratio of 1.99 and a beta of 0.96. The company has a current ratio of 0.72, a quick ratio of 0.50 and a debt-to-equity ratio of 0.58.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings results on Thursday, October 26th. The medical equipment provider reported $0.31 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.31. Boston Scientific had a net margin of 9.55% and a return on equity of 23.60%. The firm had revenue of $2.22 billion during the quarter, compared to analysts’ expectations of $2.21 billion. During the same period in the previous year, the company earned $0.27 earnings per share. Boston Scientific’s quarterly revenue was up 5.6% compared to the same quarter last year. sell-side analysts expect that Boston Scientific will post 1.25 earnings per share for the current year.

In other Boston Scientific news, EVP Supratim Bose sold 347,137 shares of the stock in a transaction that occurred on Wednesday, October 4th. The shares were sold at an average price of $29.12, for a total transaction of $10,108,629.44. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, EVP Michael P. Phalen sold 15,500 shares of the stock in a transaction that occurred on Friday, September 29th. The stock was sold at an average price of $28.72, for a total transaction of $445,160.00. The disclosure for this sale can be found here. Insiders have sold 424,698 shares of company stock worth $12,273,553 in the last three months. Insiders own 0.74% of the company’s stock.

A number of large investors have recently bought and sold shares of the business. Braun Stacey Associates grew its holdings in Boston Scientific by 40.4% during the 3rd quarter. Braun Stacey Associates now owns 348,420 shares of the medical equipment provider’s stock valued at $5,718,000 after purchasing an additional 100,185 shares in the last quarter. Janus Capital Management grew its holdings in Boston Scientific by 49.5% during the 3rd quarter. Janus Capital Management now owns 42,367,704 shares of the medical equipment provider’s stock worth $695,261,000 after acquiring an additional 14,035,306 shares in the last quarter. Churchill Management grew its holdings in Boston Scientific by 6.4% during the 4th quarter. Churchill Management now owns 209,907 shares of the medical equipment provider’s stock worth $3,871,000 after acquiring an additional 12,633 shares in the last quarter. Legacy Private Trust Company grew its holdings in Boston Scientific by 156.4% during the 4th quarter. Legacy Private Trust Company now owns 59,280 shares of the medical equipment provider’s stock worth $1,093,000 after acquiring an additional 36,160 shares in the last quarter. Finally, CIBC World Markets acquired a new position in Boston Scientific during the 4th quarter worth $1,503,000. 90.57% of the stock is currently owned by institutional investors.

COPYRIGHT VIOLATION NOTICE: This story was published by American Banking News and is the sole property of of American Banking News. If you are accessing this story on another publication, it was copied illegally and reposted in violation of US and international copyright and trademark law. The correct version of this story can be accessed at https://www.americanbankingnews.com/2017/12/12/boston-scientific-bsx-receives-buy-rating-from-bmo-capital-markets.html.

About Boston Scientific

Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven businesses: Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Pelvic Health, Neuromodulation, and Electrophysiology.

Analyst Recommendations for Boston Scientific (NYSE:BSX)

Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.